BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sane R, Cheung KWK, Kovács P, Farasyn T, Li R, Bui A, Musib L, Kis E, Plise E, Gáborik Z. Calibrating the In Vitro–In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models. Drug Metab Dispos 2020;48:1264-70. [DOI: 10.1124/dmd.120.000149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Deng F, Sjöstedt N, Santo M, Neuvonen M, Niemi M, Kidron H. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. Eur J Pharm Sci 2023;181:106362. [PMID: 36529162 DOI: 10.1016/j.ejps.2022.106362] [Reference Citation Analysis]
2 Heinig R, Fricke R, Wertz S, Nagelschmitz J, Loewen S. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3. Eur J Drug Metab Pharmacokinet 2022. [PMID: 36029368 DOI: 10.1007/s13318-022-00794-5] [Reference Citation Analysis]
3 Choi E, Han DG, Park JE, Lee HY, Yoo JW, Jung Y, Song IS, Yoon IS. A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability. J Chromatogr B Analyt Technol Biomed Life Sci 2022;1208:123399. [PMID: 35921698 DOI: 10.1016/j.jchromb.2022.123399] [Reference Citation Analysis]
4 Chu X, Chan GH, Houle R, Lin M, Yabut J, Fandozzi C. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. AAPS J 2022;24. [DOI: 10.1208/s12248-021-00677-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Braeuning A, Bloch D, Karaca M, Kneuer C, Rotter S, Tralau T, Marx-stoelting P. An approach for mixture testing and prioritization based on common kinetic groups. Arch Toxicol. [DOI: 10.1007/s00204-022-03264-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Costales C, Lin J, Kimoto E, Yamazaki S, Gosset JR, Rodrigues AD, Lazzaro S, West MA, West M, Varma MVS. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34164937 DOI: 10.1002/psp4.12672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
7 Sane RS, Cheung KWK, Cho E, Liederer BM, Hanover J, Malhi V, Plise E, Wong S, Musib L. Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects. J Pharmacol Exp Ther 2021;378:87-95. [PMID: 34049965 DOI: 10.1124/jpet.121.000620] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]